Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

79.98CHF
4:31pm GMT
Change (% chg)

CHF-0.22 (-0.27%)
Prev Close
CHF80.20
Open
CHF79.72
Day's High
CHF80.30
Day's Low
CHF79.44
Volume
3,857,763
Avg. Vol
4,980,705
52-wk High
CHF88.30
52-wk Low
CHF72.45

Select another date:

BRIEF-Novartis AG Says Ultibro Breezhaler Improved Cardiac Function In COPD Patients With Lung Hyperinflation‍​

* SAYS TREATMENT WITH NOVARTIS' ULTIBRO BREEZHALER IMPROVED CARDIAC FUNCTION IN COPD PATIENTS WITH LUNG HYPERINFLATION‍​ Further company coverage: (Reporting by John Miller)

MEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJ

Note: Reuters has not verified this story and cannot vouch for its accuracy. (New York Newsroom)

Novartis readies to auction U.S. generic pills business: sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

Novartis readies to auction U.S. generic pills business - sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

CORRECTED-Novartis readies to auction U.S. generic pills business -sources

Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

BRIEF-Novartis forms alliance for treating infectious diarrheal disease

* NOVARTIS FORMS ALLIANCE TO DEVELOP MEDICINES FOR TREATING INFECTIOUS DIARRHEAL DISEASE

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

UPDATE 2-Novartis gains U.S. approval for delayed MS drug

* U.S. pricing pressure weighing on Sandoz (Adds Teva comment, share price reaction)

Novartis gets U.S. approval for bigger dose Glatopa MS treatment

ZURICH, Feb 13 Novartis's Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.

Select another date: